abhayrab 2,5 iu pulbere şi solvent pentru soluţie injectabilă
human biologicals institute (a division of indian immunologicals limited)) - final bulk for rabies human monoclonal antibody - pulbere şi solvent pentru soluţie injectabilă - 2,5 iu
rabishield-100 100 ui/2,5 ml soluţie injectabilă
serum institute of india pvt.ltd - final bulk for rabies human monoclonal antibody - soluţie injectabilă - 100 ui/2,5 ml
finalgon 4 mg/25 mg/g
boehringer ingelheim pharma gmbh & co. kg - germania - combinatii - unguent - 4mg/25mg/g - medicamente topice pentru dureri articulare si musculare preparate cu capsicum
finalgon 4 mg/25 mg/g
globopharm - austria - combinatii - unguent - 4mg/25mg/g - medicamente topice pentru dureri articulare si musculare preparate cu capsicum
finalgon 4 mg/25 mg/g
globopharm - austria - combinatii (nonivamidum+nicoboxilum) - unguent - 4mg/25mg/g - medicamente topice pentru dureri articulare si musculare preparate cu capsicum
finalgon 4 mg/25 mg/ g
boehringer ingelheim international gmbh - combinatii - unguent - 4mg/25mg/g - medicamente topice pentru dureri articulare si musculare preparate cu capsicum
finalgon 4 mg + 25 mg/g unguent
sanofi romania srl - nonivamidum + nicoboxilum - unguent - 4 mg + 25 mg/g
finalgon 4 mg/25 mg/g unguent
zentiva sa - nonivamidum + nicoboxilum - unguent - 4 mg/25 mg/g
nivolumab bms
bristol-myers squibb pharma eeig - nivolumab - carcinom, pulmonar non-celulă mică - antineoplazice si imunomodulatoare, anticorpi monoclonali - nivolumab bms este indicat pentru tratamentul cancerului pulmonar cu celule mici nemetalopatii (nsclc) avansat la nivel local sau metastatic, dupa chimioterapia anterioara la adulti.
pepaxti
oncopeptides ab - melphalan flufenamide hydrochloride - mielom multiplu - agenți antineoplazici - pepaxti is indicated, in combination with dexamethasone, for the treatment of adult patients with multiple myeloma who have received at least three prior lines of therapies, whose disease is refractory to at least one proteasome inhibitor, one immunomodulatory agent, and one anti-cd38 monoclonal antibody, and who have demonstrated disease progression on or after the last therapy. for patients with a prior autologous stem cell transplantation, the time to progression should be at least 3 years from transplantation (see section 4.